Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | SGMS2 | Q8NHU3 | 6/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1201041 | 0.88 | TSHR (0.36) | TSHRALDH1A1CYP1A2KDM4EMEN1 | |
| SCHEMBL1200839 | 0.82 | TSHR (0.41) | TSHRALDH1A1CYP1A2KDM4ECYP2C9 | |
| SCHEMBL1200542 | 0.80 | CTDSP1 (0.46) | TSHRALDH1A1CYP1A2KDM4EMEN1 | |
| SCHEMBL1199570 | 0.78 | TSHR (0.47) | TSHRALDH1A1CYP1A2KDM4EMEN1 | |
| SCHEMBL22144397 | 0.78 | TSHR (0.47) | TSHRALDH1A1CYP1A2KDM4EMEN1 | |
| SCHEMBL1200658 | 0.77 | TSHR (0.37) | TSHRALDH1A1 | |
| SCHEMBL27836366 | 0.76 | PPARG (0.41) | TSHRALDH1A1CYP1A2KDM4EMEN1 | |
| SCHEMBL1901084 | 0.76 | PPARG (0.41) | TSHRALDH1A1CYP1A2KDM4EMEN1 | |
| SCHEMBL1200910 | 0.75 | ELANE (0.43) | TSHRALDH1A1CYP1A2KDM4EMEN1 | |
| SCHEMBL1899824 | 0.75 | CYP1A2 (0.47) | ALDH1A1CYP1A2KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309753-B2 | Method for producing optically active cyanohydrin compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20110034718-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2264005-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034718-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND | CBR3, ACSL3, CCNL2 | TSHR 4501/4885ALDH1A1 129/4885CYP1A2 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.